HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 293/2/E460    most recent 00149.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Dubé, P. E. Articles by Brubaker, P. L. Search for Related Content PubMed PubMed Citation Articles by Dubé, P. E. Articles by Brubaker, P. L.

FRONTIERS

Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators

Departments of ¹Physiology and ²Medicine, University of Toronto, Toronto, Ontario, Canada

Submitted 7 March 2007 ; accepted in final form 13 April 2007

ABSTRACT

Glucagon-like peptide-2 (GLP-2) is a pleiotropic hormone that affects multiple facets of intestinal physiology, including growth, barrier function, digestion, absorption, motility, and blood flow. The mechanisms through which GLP-2 produces these actions are complex, involving unique signaling mechanisms and multiple indirect mediators. As clinical trials have begun for the use of GLP-2 in a variety of intestinal disorders, the elucidation of such mechanisms is vital. The GLP-2 receptor (GLP-2R) is a G protein-coupled receptor, signaling through multiple G proteins to affect the cAMP and mitogen-activated protein kinase pathways, leading to both proliferative and antiapoptotic cellular responses. The GLP-2R also demonstrates unique mechanisms for receptor trafficking. Expression of the GLP-2R in discrete sets of intestinal cells, including endocrine cells, subepithelial myofibroblasts, and enteric neurons, has led to the hypothesis that GLP-2 acts indirectly through multiple mediators to produce its biological effects. Indeed, several studies have now provided important mechanistic data illustrating several of the indirect pathways of GLP-2 action. Thus, insulin-like growth factor I has been demonstrated to be required for GLP-2-induced crypt cell proliferation, likely involving activation of -catenin signaling. Furthermore, vasoactive intestinal polypeptide modulates the actions of GLP-2 in models of intestinal inflammation, while keratinocyte growth factor is required for GLP-2-induced colonic mucosal growth and mucin expression. Finally, enteric neural GLP-2R signaling affects intestinal blood flow through a nitric oxide-dependent mechanism. Determining how GLP-2 produces its full range of biological effects, which mediators are involved, and how these mediators interact is a continuing area of active research.

growth; intestine; receptor; signaling

This article has been cited by other articles:

				X. Liu, S. G. Murali, J. J. Holst, and D. M. Ney Whey protein potentiates the intestinotrophic action of glucagon-like peptide-2 in parenterally fed rats Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1554 - R1562. [Abstract] [Full Text] [PDF]

				S. Baldassano, S. Liu, M.-H. Qu, F. Mule, and J. D. Wood Glucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro Am J Physiol Gastrointest Liver Physiol, October 1, 2009; 297(4): G800 - G805. [Abstract] [Full Text] [PDF]

				P D Cani, S Possemiers, T Van de Wiele, Y Guiot, A Everard, O Rottier, L Geurts, D Naslain, A Neyrinck, D M Lambert, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability Gut, August 1, 2009; 58(8): 1091 - 1103. [Abstract] [Full Text] [PDF]

				H. Izumi, S. Ishizuka, A. Inafune, T. Hira, K. Ozawa, T. Shimizu, M. Takase, and H. Hara {alpha}-Lactalbumin Hydrolysate Stimulates Glucagon-Like Peptide-2 Secretion and Small Intestinal Growth in Suckling Rats J. Nutr., July 1, 2009; 139(7): 1322 - 1327. [Abstract] [Full Text] [PDF]

				A. Amato, S. Baldassano, R. Serio, and F. Mule Glucagon-like peptide-2 relaxes mouse stomach through vasoactive intestinal peptide release Am J Physiol Gastrointest Liver Physiol, March 1, 2009; 296(3): G678 - G684. [Abstract] [Full Text] [PDF]

				A. P. Garrison, C. M. Dekaney, D. C. von Allmen, P. K. Lund, S. J. Henning, and M. A. Helmrath Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion Am J Physiol Gastrointest Liver Physiol, March 1, 2009; 296(3): G643 - G650. [Abstract] [Full Text] [PDF]

				X. Liu, S. G. Murali, J. J. Holst, and D. M. Ney Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2008; 295(6): R1794 - R1802. [Abstract] [Full Text] [PDF]